Cytosorbents (CTSO) Current Assets (2010 - 2026)

Cytosorbents has reported Current Assets for 17 years, with the latest figure at $17.8 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 30.13% year-over-year to $17.8 million; the trailing twelve-month figure through Mar 2026 stood at $17.8 million (down 30.13% YoY), and the FY2025 full-year result was $20.6 million, down 4.49% from the prior year.
• Current Assets for Q1 2026 stood at $17.8 million, down from $20.6 million in the prior quarter.
• The five-year high for Current Assets was $55.9 million in Q1 2022, with the low at $16.6 million in Q3 2024.
• Historically, Current Assets has averaged $26.4 million across 5 years, with a median of $23.0 million in 2025.
• Annual changes were most pronounced in 2022 — Current Assets plunged 55.49% — and 2025, when it grew 28.41%.
• Cytosorbents' Current Assets stood at $33.8 million in 2022, then retreated by 24.77% to $25.4 million in 2023, then retreated by 14.94% to $21.6 million in 2024, then decreased by 4.49% to $20.6 million in 2025, then retreated by 13.94% to $17.8 million in 2026.
• The last three Current Assets figures came in at $17.8 million (Q1 2026), $20.6 million (Q4 2025), and $21.3 million (Q3 2025), per Business Quant data.